Skip to main content

Advertisement

SpringerLink
Log in

Post-transplantation lymphoproliferative disorder (PTLD) twenty years after heart transplantation: a case report and review of the literature

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

We report a 62-year-old man who developed biopsy-proven post-transplantation lymphoproliferative disorder (PTLD) 20 years after receiving a heart transplant while being treated with immunosuppressive agents. The patient presented with large retroperitoneal and intestinal wall masses that caused partial gastrointestinal stenosis. Monoclonal antibody against CD20 in conjunction with chemotherapy and tapering of the immunosuppressive regimen was instituted, resulting in objective response of the disease bulk. To the best of our knowledge, this is the second reported case of PTLD 20 years after heart transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yamani MH, Taylor DO, Haire C, Smedira N, Starling RC. Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression. Clin Transplant. 2007;21:523–5.

    Article  PubMed  CAS  Google Scholar 

  2. Roithmaier S, et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant. 2007;26:845–9.

    Article  PubMed  Google Scholar 

  3. Leblond V, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19:772–8.

    PubMed  CAS  Google Scholar 

  4. Ghobrial IM, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23:7574–82.

    Article  PubMed  Google Scholar 

  5. Choquet S, Levy V, Leblond V. Identification of prognostic factors in post-transplantation lymphoproliferative disorders. Bull Cancer. 2004;91:373–8.

    PubMed  Google Scholar 

  6. Tsai DE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076–88.

    Article  PubMed  CAS  Google Scholar 

  7. LaCasce AS. Post-transplant lymphoproliferative disorders. Oncologist. 2006;11(6):674–80.

    Article  PubMed  Google Scholar 

  8. Schubert S, et al. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant. 2008;27(1):100–5.

    Article  PubMed  Google Scholar 

  9. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis. 2001;33(Suppl 1):S38–46.

    Article  PubMed  Google Scholar 

  10. Wasson S, Zafar MN, Best J, Reddy HK. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience. J Cardiovasc Pharmacol Ther. 2006;11(1):77–83.

    Article  PubMed  Google Scholar 

  11. Swinnen LJ, Fischer RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. Curr Opin Nephrol Hypertens. 1993;2:670–8.

    PubMed  CAS  Google Scholar 

  12. Opel ZG, Dohler G. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–30.

    Article  Google Scholar 

  13. Keever-Taylor CA, et al. Complement-mediated T-cell depletion of bone marrow: comparison of T10B9. 1A–31 and Muromonab-Orthoclone OKT3. Cytotherapy. 2001;3(6):467–81.

    Article  PubMed  CAS  Google Scholar 

  14. Ciancio G, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant. 1997;11(3):243–9.

    PubMed  CAS  Google Scholar 

  15. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–92.

    Article  PubMed  CAS  Google Scholar 

  16. Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer. 2009;125(8):1755–63.

    Article  PubMed  CAS  Google Scholar 

  17. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A. 1984;81:3806–10.

    Article  PubMed  CAS  Google Scholar 

  18. Johannsen E, et al. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU. 1. J Virol. 1995;69:253–62.

    PubMed  CAS  Google Scholar 

  19. Wang F, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990;64:2309–18.

    PubMed  CAS  Google Scholar 

  20. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol. 2005;23:61–7.

    Article  PubMed  Google Scholar 

  21. Bräuninger A, et al. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Eur J Immunol. 2003;33:1593–602.

    Article  PubMed  Google Scholar 

  22. Mosialos G, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995;80:389–99.

    Article  PubMed  CAS  Google Scholar 

  23. Capello D, Berra E, Cerri M, Gaidano G. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis. Minerva Med. 2004;95:53–64.

    PubMed  CAS  Google Scholar 

  24. Novoa-Takara L, et al. Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation. Am J Clin Pathol. 2005;123:104–12.

    Article  PubMed  Google Scholar 

  25. Paya CV, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD task force and the mayo clinic organized international consensus development meeting. Transplantation. 1999;68:1517–25.

    Article  PubMed  CAS  Google Scholar 

  26. Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis. 2001;3:97–103.

    Article  PubMed  CAS  Google Scholar 

  27. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 2003;45(1):1–36.

    Article  PubMed  Google Scholar 

  28. Davis CL, et al. Interferon-alpha treatment in post-transplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66:1770–9.

    Article  PubMed  CAS  Google Scholar 

  29. Choquel S, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3053–7.

    Article  Google Scholar 

  30. Choquet S, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007;86:599–607.

    Article  PubMed  CAS  Google Scholar 

  31. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133–9.

    Article  PubMed  CAS  Google Scholar 

  32. Montesinos P, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67–74.

    Article  PubMed  CAS  Google Scholar 

  33. Alavi S, Arzanian MT, Abbasian MR, Ashena Z. Tumor lysis syndrome in children with non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2006;23(1):65–70.

    Article  PubMed  Google Scholar 

  34. Kaleem Z, Hassan A, Pathan MH, White G. Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders. Arch Pathol Lab Med. 2004;128:181–6.

    PubMed  Google Scholar 

  35. Buadi FK, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol. 2007;82(3):208–14.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We acknowledge Dr Steve Hou and Dr Jabed Iqbal from the Department of Pathology for their significant contributions in the interpretation of the pathology report.

Conflict of interest statement

None declared.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, 19102, USA

    Petros D. Grivas

Authors
  1. Petros D. Grivas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petros D. Grivas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grivas, P.D. Post-transplantation lymphoproliferative disorder (PTLD) twenty years after heart transplantation: a case report and review of the literature. Med Oncol 28, 829–834 (2011). https://doi.org/10.1007/s12032-010-9523-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9523-2

Keywords

Search

Navigation